Inclusion Criteria:

          -  Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of
             system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and
             anti-CD38 antibody (CD38mab); or has "triple-refractory" disease

          -  Documented measurable disease

          -  Adequate organ function

          -  Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1

        Exclusion Criteria:

          -  Plasma Cell Leukemia or History of Plasma Cell Leukemia

          -  Patients with a history of severe hypersensitivity to DMSO should be excluded

          -  Contraindication to fludarabine or cyclophosphamide

          -  Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities

          -  Active central nervous system disease involvement by malignancy or active CNS
             pathology